WO2007033208A3 - Use of indirubin and its derivatives in the treatments of hiv infection and heart failure - Google Patents
Use of indirubin and its derivatives in the treatments of hiv infection and heart failure Download PDFInfo
- Publication number
- WO2007033208A3 WO2007033208A3 PCT/US2006/035559 US2006035559W WO2007033208A3 WO 2007033208 A3 WO2007033208 A3 WO 2007033208A3 US 2006035559 W US2006035559 W US 2006035559W WO 2007033208 A3 WO2007033208 A3 WO 2007033208A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- indirubin
- derivatives
- polypeptide sequence
- heart failure
- treatments
- Prior art date
Links
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 title abstract 8
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 title abstract 4
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 title abstract 4
- 206010019280 Heart failures Diseases 0.000 title abstract 2
- 208000031886 HIV Infections Diseases 0.000 title 1
- 208000037357 HIV infectious disease Diseases 0.000 title 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 108070000030 Viral receptors Proteins 0.000 abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 230000027902 cell growth involved in cardiac muscle cell development Effects 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Indirubin and its derivatives are described for reduction of replication of human immunodeficiency virus. Such therapeutic agent and its derivatives are also described in application to reducing the effects of heart failure, by administration of indirubin or a functionally active derivative thereof to modify cardiac muscle cell hypertrophy. Indirubin and its functional derivatives may also be employed in antiviral combination therapy compositions containing therapeutically effective chimeric polypeptides containing a virus coat polypeptide sequence and a viral receptor polypeptide sequence wherein the virus coat polypeptide sequence and the viral receptor polypeptide sequence are linked and exhibit ligand/receptor binding affinity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71609705P | 2005-09-12 | 2005-09-12 | |
| US60/716,097 | 2005-09-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2007033208A2 WO2007033208A2 (en) | 2007-03-22 |
| WO2007033208A3 true WO2007033208A3 (en) | 2009-05-22 |
Family
ID=37865533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2006/035559 WO2007033208A2 (en) | 2005-09-12 | 2006-09-12 | Use of indirubin and its derivatives in the treatments of hiv infection and heart failure |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2007033208A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2716838C (en) * | 2008-02-29 | 2014-01-07 | Schering Corporation | Ccr5 antagonists as prophylactics for preventing hiv infection and methods of inhibiting transmission of same |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596539B1 (en) * | 1997-10-31 | 2003-07-22 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
| US20040254094A1 (en) * | 2000-10-11 | 2004-12-16 | The Trustees Of University Of Pennsylvania And Board Of Regents | Suppression of cyclin kinase activity for prevention and treatment of infections |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20050171038A1 (en) * | 2004-01-30 | 2005-08-04 | Agouron Pharmaceuticals, Inc. | Therapeutic combinations |
-
2006
- 2006-09-12 WO PCT/US2006/035559 patent/WO2007033208A2/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596539B1 (en) * | 1997-10-31 | 2003-07-22 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
| US20040254094A1 (en) * | 2000-10-11 | 2004-12-16 | The Trustees Of University Of Pennsylvania And Board Of Regents | Suppression of cyclin kinase activity for prevention and treatment of infections |
| US20050154046A1 (en) * | 2004-01-12 | 2005-07-14 | Longgui Wang | Methods of treating an inflammatory-related disease |
| US20050171038A1 (en) * | 2004-01-30 | 2005-08-04 | Agouron Pharmaceuticals, Inc. | Therapeutic combinations |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007033208A2 (en) | 2007-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2007022371A3 (en) | Chemokine receptor binding compounds | |
| EP1521749B8 (en) | PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES | |
| WO2005121145A3 (en) | Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds | |
| MXPA03010402A (en) | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine derivatives. | |
| EP1834637A4 (en) | Preventive/therapeutic composition for free radical disease | |
| WO2006034373A3 (en) | Variants and chemically-modified variants of phenylalanine ammonia-lyase | |
| WO2008054454A3 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
| DK1079806T3 (en) | Preparations for the application of anti-inflammatory, in particular antiseptic agents and / or agents promoting the healing of wounds, to the upper respiratory tract and / or the ear | |
| WO2007064968A3 (en) | Stable pharmaceutical compositions of 5,10 methylenetetrahydrofolate | |
| WO2007046868A3 (en) | Thiazolidine derivatives and their uses as therapeutic agents | |
| MX2007004882A (en) | Xanthine derivatives with hm74a receptor activity. | |
| WO2009093264A3 (en) | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | |
| WO2002074056A3 (en) | Allosteric adenosine receptor modulators | |
| JP2002528502A5 (en) | ||
| WO2006125194A3 (en) | Piperazine derivatives and their uses as therapeutic agents | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| RU2004135563A (en) | MEDICINE FOR TREATING AN INCREASED ACTIVITY OF THE BLADDER | |
| JP2004537500A5 (en) | ||
| WO2006138350A3 (en) | Chemokine receptor binding compounds | |
| WO2006088945A3 (en) | Granulysin peptides and methods of use thereof | |
| WO2005059107A3 (en) | Chemokine receptor binding compounds | |
| CA2143610A1 (en) | Use of norastemizole for the treatment of allergic disorders | |
| NZ703919A (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| WO2005094554A3 (en) | Therapeutic agents, methods, and treatments | |
| WO2007033208A3 (en) | Use of indirubin and its derivatives in the treatments of hiv infection and heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 06803464 Country of ref document: EP Kind code of ref document: A2 |